Shandong Keyuan Pharmaceutical Co., Ltd. Class A

Shandong Keyuan Pharmaceutical Co., Ltd. Class A

SSZSE:301281
34.27
CNY
-1.48
(-4.14%)
0.66EPS
72.65P/E
5.12BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.64
9.5
2.74
2.57
3.14
3.33
3.83
4.51
5.19
5.43
4.42
4.3
3.61
5.34
Basic EPS, GAAP
0.01
0.66
0.32
0.47
0.57
0.35
0.37
0.84
0.96
1.12
0.76
0.56
0.15
0.65
Free Cash Flow per Basic Share
0.22
0.1
0.27
-0.27
-0.52
-0.49
-0.19
1.2
0.39
1.04
-0.33
-3.31
-0.85
- -
Dividend per Share
0.04
0.26
0.06
0.01
0.02
0.26
0.04
0.02
- -
- -
0.31
0.3
0.22
0.1
Book Value per Share
0.19
0.31
0.78
1.17
3.12
3.78
3.37
4.21
5.31
6.4
12.29
12.55
12.52
13.48
Tangible Book Value per Share
0.09
0.15
0.6
0.97
2.94
3.03
2.66
3.53
4.67
5.8
11.87
11.52
11.44
11.52
Basic Weighted Avg Shares
81
14
45
70
76
81
81
81
81
81
101
108
110
108
Sales/Revenue/Turnover
133
133
123
180
239
271
311
367
421
443
448
464
398
578
Operating Margin (%)
4.44
10.48
14.67
20.74
22.18
14.52
16.03
22.28
21.42
22.27
14.67
13.29
11.2
20.27
Depreciation Expense
8
7
7
7
10
20
24
25
27
34
49
47
52
- -
Net Income, GAAP
1
9
14
33
44
28
30
69
78
91
77
60
17
70
Effective Tax Rate (%)
13.19
17.39
14.56
14.65
15.64
14.77
23.8
15.33
13.06
7.14
3.38
8.27
2.39
12.64
Profit Margin (%)
0.66
6.99
11.73
18.35
18.2
10.5
9.69
18.7
18.57
20.61
17.21
13.04
4.16
12.18
Working Capital
-64
-52
-15
-7
74
24
-7
77
93
174
768
571
476
419
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
46
112
119
Total Equity
15
26
63
95
253
307
273
342
431
520
1,331
1,360
1,356
1,462
Return on Invested Capital (%)
- -
17.36
21.77
33.5
23.82
9.68
8.83
19.13
20.23
19.18
8.36
4.58
2.2
5.24
Return on Capital (%)
- -
25.68
25.67
37.68
24.99
10.69
13.56
22.59
20.24
19.2
8.33
4.43
1.17
4.42
Return on Common Equity (%)
- -
45.46
32.45
41.62
25.05
10.17
10.39
22.33
20.24
19.2
8.33
4.49
1.22
4.96

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
39
83
100
LT Borrowings
117
120
119
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
108
108
108
Market Capitalization
3,846
5,339
5,117

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
732
764
775
Cash, Cash Equivalents & STI
364
242
337
Accounts Receivable, Net
175
211
246
Inventories
141
127
127
Total Current Liabilities
240
332
356
Payables & Accruals
- -
- -
- -
ST Debt
39
83
100
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
45.65%
40.95%
-0.25%
Free Cash Flow
-8.03%
172.71%
-73.78%
Net Income, GAAP
18.07%
-15.82%
-72.62%
Sales/Revenue/Turnover
13.59%
2.09%
-14.12%
Total Cash Common Dividend
- -
- -
-23.78%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
146
91
94
133
464
2025
111
117
- -
96
398
2026
161
170
151
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.13
0.03
0.19
0.56
2025
0.21
0.18
- -
-0.14
0.15
2026
0.28
0.32
0.19
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.3
2025
- -
- -
- -
0.01
0.22
2026
0.01
0.06
0.02
- -
- -

Company Description

Full Time Employees
650
Sector
Process industries
Industry
Chemicals: specialty
Address
Jinan China
IPO Date
Apr 4, 2023
Business
Shandong Keyuan Pharmaceutical Co., Ltd. is a China-based pharmaceutical company that researches, develops, manufactures, and markets active pharmaceutical ingredients (APIs), chemical intermediates, and finished dosage formulations. The company operates across multiple therapeutic categories, offering chemical APIs and intermediate compounds, including anti-diabetic agents such as metformin hydrochloride, gliclazide, and vildagliptin; cardiovascular medications such as isosorbide mononitrate, isosorbide dinitrate, and esmolol hydrochloride; psychiatric and central nervous system treatments such as fluoxetine hydrochloride and lurasidone hydrochloride; anesthetic agents such as ropivacaine hydrochloride and isoflurane; and other chemical intermediates such as clarithromycin lactobionate, xanthinol nicotinate, and amlexanox. Through its wholly owned subsidiary Shandong Linuo Pharmaceutical Co., Ltd., the company produces and distributes finished chemical preparations across various delivery forms, including oral solid tablets and capsules; oral liquids; injectable solutions; topical liniments, pastes, and drops; and aerosol sprays. Additionally, the company provides international contract manufacturing organization (CMO) and custom synthesis services for global pharmaceutical innovators, alongside an expanding product portfolio encompassing pharmaceutical excipients, cosmetic raw materials, and functional health additives under its integrated API-plus business model. Founded in 2004 and headquartered in Jinan, Shandong Province, China, Shandong Keyuan Pharmaceutical operates as a core pharmaceutical unit of Linuo Group, serving domestic healthcare institutions and commercial clients while exporting to nearly 200 customers across more than 50 countries and regions throughout Asia, Europe, North America, and South America under regulatory accreditations from the US FDA, EDQM, PMDA, and MFDS. In recent operational and corporate developments, following its public listing on the Shenzhen Stock Exchange ChiNext board in April 2023, the company pursued internal asset consolidation within Linuo Group through a proposed multi-billion-yuan acquisition of traditional Chinese medicine producer Shandong Hongjitang Pharmaceutical Group Co., Ltd., which was initiated in late 2024 and subsequently terminated in late 2025 due to changing capital market conditions; the company has since refocused capital and operational resources on its core chemical API and formulation capabilities, securing recent regulatory approvals for new pipeline products such as rotigotine API while expanding capacity across its specialized chronic disease treatment lines.